Literature DB >> 10523583

Effects of OspA vaccination on Lyme disease serologic testing.

M E Aguero-Rosenfeld1, J Roberge, C A Carbonaro, J Nowakowski, R B Nadelman, G P Wormser.   

Abstract

This study presents the effects of OspA vaccination on two-step testing for Borrelia burgdorferi antibodies. Although vaccinees developed enzyme-linked immunosorbent assay reactivity, immunoblots did not fulfill Centers for Disease Control and Prevention criteria for positivity. Furthermore, OspA reactivity did not interfere with interpretation of immunoblots with sera from patients who developed early Lyme disease despite vaccination.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10523583      PMCID： PMC85737     

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  12 in total

1.  Serodiagnosis of Lyme disease: accuracy of a two-step approach using a flagella-based ELISA and immunoblotting.

Authors:  B J Johnson; K E Robbins; R E Bailey; B L Cao; S L Sviat; R B Craven; L W Mayer; D T Dennis
Journal:  J Infect Dis       Date:  1996-08       Impact factor: 5.226

2.  Guidelines for laboratory evaluation in the diagnosis of Lyme disease. American College of Physicians.

Authors: 
Journal:  Ann Intern Med       Date:  1997-12-15       Impact factor: 25.391

3.  Laboratory evaluation in the diagnosis of Lyme disease.

Authors:  P Tugwell; D T Dennis; A Weinstein; G Wells; B Shea; G Nichol; R Hayward; R Lightfoot; P Baker; A C Steere
Journal:  Ann Intern Med       Date:  1997-12-15       Impact factor: 25.391

4.  Accuracy of IgM immunoblotting to confirm the clinical diagnosis of early Lyme disease.

Authors:  S L Sivak; M E Aguero-Rosenfeld; J Nowakowski; R B Nadelman; G P Wormser
Journal:  Arch Intern Med       Date:  1996-10-14

5.  Utilization and cost of serologic tests for Lyme disease in Maryland.

Authors:  G T Strickland; A C Karp; A Mathews; C A Peña
Journal:  J Infect Dis       Date:  1997-09       Impact factor: 5.226

6.  Borrelia burgdorferi enzyme-linked immunosorbent assay for discrimination of OspA vaccination from spirochete infection.

Authors:  Y Q Zhang; D Mathiesen; C P Kolbert; J Anderson; R T Schoen; E Fikrig; D H Persing
Journal:  J Clin Microbiol       Date:  1997-01       Impact factor: 5.948

7.  Recommendations for test performance and interpretation from the Second National Conference on Serologic Diagnosis of Lyme Disease.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  1995-08-11       Impact factor: 17.586

8.  Immunoblot interpretation criteria for serodiagnosis of early Lyme disease.

Authors:  S M Engstrom; E Shoop; R C Johnson
Journal:  J Clin Microbiol       Date:  1995-02       Impact factor: 5.948

Review 9.  Prospects for a vaccine to prevent Lyme disease in humans.

Authors:  G P Wormser
Journal:  Clin Infect Dis       Date:  1995-11       Impact factor: 9.079

10.  Vaccination against Lyme disease with recombinant Borrelia burgdorferi outer-surface lipoprotein A with adjuvant. Lyme Disease Vaccine Study Group.

Authors:  A C Steere; V K Sikand; F Meurice; D L Parenti; E Fikrig; R T Schoen; J Nowakowski; C H Schmid; S Laukamp; C Buscarino; D S Krause
Journal:  N Engl J Med       Date:  1998-07-23       Impact factor: 91.245
View more
  9 in total

Review 1.  Laboratory testing for Lyme disease: possibilities and practicalities.

Authors:  Kurt D Reed
Journal:  J Clin Microbiol       Date:  2002-02       Impact factor: 5.948

2.  Evaluation of the C6 peptide enzyme-linked immunosorbent assay for individuals vaccinated with the recombinant OspA vaccine.

Authors:  Adriana R Marques; Dale S Martin; Mario T Philipp
Journal:  J Clin Microbiol       Date:  2002-07       Impact factor: 5.948

3.  OspE-related, OspF-related, and Elp lipoproteins are immunogenic in baboons experimentally infected with Borrelia burgdorferi and in human lyme disease patients.

Authors:  P Scott Hefty; Chad S Brooks; Amy M Jett; Gary L White; Stephen K Wikel; Ronald C Kennedy; Darrin R Akins
Journal:  J Clin Microbiol       Date:  2002-11       Impact factor: 5.948

4.  Adjuvanted Lyme disease vaccine: a review of its use in the management of Lyme disease.

Authors:  S V Onrust; K L Goa
Journal:  Drugs       Date:  2000-02       Impact factor: 9.546

5.  Effect of immunization with recombinant OspA on serologic tests for Lyme borreliosis.

Authors:  P T Fawcett; C D Rose; S M Budd; K M Gibney
Journal:  Clin Diagn Lab Immunol       Date:  2001-01

Review 6.  Diagnosis of lyme borreliosis.

Authors:  Maria E Aguero-Rosenfeld; Guiqing Wang; Ira Schwartz; Gary P Wormser
Journal:  Clin Microbiol Rev       Date:  2005-07       Impact factor: 26.132

7.  Recombinant assay for serodiagnosis of Lyme disease regardless of OspA vaccination status.

Authors:  Maria J C Gomes-Solecki; Gary P Wormser; Martin Schriefer; Glenn Neuman; Laura Hannafey; John D Glass; Raymond J Dattwyler
Journal:  J Clin Microbiol       Date:  2002-01       Impact factor: 5.948

Review 8.  Lyme disease: an update.

Authors:  A R Marques
Journal:  Curr Allergy Asthma Rep       Date:  2001-11       Impact factor: 4.806

9.  Long-term effects of immunization with recombinant lipoprotein outer surface protein a on serologic test for lyme disease.

Authors:  Paul T Fawcett; Carlos D Rose; Victoria Maduskuie
Journal:  Clin Diagn Lab Immunol       Date:  2004-07
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.